MISSISSAUGA, ON, July 8, 2025 /CNW/ -- Abbott (NYSE: ABT) today announced that its latest generation of sensor-based glucose monitoring technology, the FreeStyle Libre 3 Plus * sensor, is now ...

Mary is an associate editor covering technology, culture and everything in between. She recently graduated from the University of North Carolina at Chapel Hill, where she served as an editor at The ...

Monitoring your blood sugar level no longer requires you to draw blood. The U.S. Food and Drug Administration (FDA) has approved a device that will bring diabetes patients into the 21st century of ...

ABBOTT PARK, Ill., Sept. 28, 2020 /PRNewswire/ -- Abbott (NYSE: ABT), the worldwide leader in continuous glucose monitoring (CGM) technology, 8 announced today it has secured CE Mark (Conformité ...

Credit: Abbott. The FreeStyle Libre 3 reader is a standalone, small handheld device that displays real-time glucose readings. The Food and Drug Administration (FDA) has cleared a standalone reader to ...

ABBOTT PARK, Ill., Jan. 4, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the FreeStyle ® Libre System, the company's revolutionary new continuous glucose monitoring (CGM) system, is now ...

The Freestyle Libre 14 day is now the longest-lasting self-applied continuous glucose sensing technology available and allows the used to wear the sensor for up to 14 days with high accuracy. ABBOTT ...

Glucose monitoring is key to effective diabetes management as it helps people living with diabetes understand how their body responds to food, exercise, and medications 3. It empowers them to take an ...